Zacks Research Analysts Boost Earnings Estimates for Sanofi
Sanofi (NASDAQ:SNY - Free Report) - Analysts at Zacks Research lifted their Q1 2025 EPS estimates for Sanofi in a note issued to investors on Wednesday, January 22nd. Zacks Research analyst K. Shah now anticipates that the company will earn $0.85 per share for the quarter, up from their prior estimate of $0.84. The consensus estimate for Sanofi's current full-year earnings is $3.82 per share. Zacks Research also issued estimates for Sanofi's Q2 2025 earnings at $0.94 EPS, Q4 2025 earnings at $1.10 EPS, FY2025 earnings at $4.47 EPS and Q3 2026 earnings at $1.47 EPS.
Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating the consensus estimate of $0.22 by $1.35. The business had revenue of $13.44 billion during the quarter, compared to analysts' expectations of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business's revenue for the quarter was up 12.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.55 EPS.
Separately, StockNews.com lowered Sanofi from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th.
View Our Latest Stock Report on SNY
SNY opened at $52.48 on Monday. The stock has a market capitalization of $133.19 billion, a PE ratio of 26.78, a P/E/G ratio of 1.19 and a beta of 0.57. Sanofi has a one year low of $45.22 and a one year high of $58.97. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The business's 50 day moving average price is $48.70 and its 200 day moving average price is $52.20.
Large investors have recently made changes to their positions in the stock. Stablepoint Partners LLC increased its holdings in Sanofi by 0.8% in the 3rd quarter. Stablepoint Partners LLC now owns 23,893 shares of the company's stock valued at $1,377,000 after purchasing an additional 189 shares during the last quarter. Abel Hall LLC grew its stake in shares of Sanofi by 1.8% in the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company's stock valued at $530,000 after buying an additional 194 shares in the last quarter. PDS Planning Inc raised its holdings in shares of Sanofi by 3.1% in the 3rd quarter. PDS Planning Inc now owns 6,643 shares of the company's stock valued at $383,000 after buying an additional 200 shares during the period. Eagle Ridge Investment Management lifted its stake in Sanofi by 3.8% during the 3rd quarter. Eagle Ridge Investment Management now owns 5,571 shares of the company's stock worth $321,000 after acquiring an additional 203 shares in the last quarter. Finally, Financial Advocates Investment Management boosted its holdings in Sanofi by 3.4% during the 3rd quarter. Financial Advocates Investment Management now owns 6,327 shares of the company's stock valued at $365,000 after acquiring an additional 206 shares during the period. 14.04% of the stock is currently owned by institutional investors and hedge funds.
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
